2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1545
    ACTH (1-17) 7266-47-9 98%
    ACTH (1-17), an adrenocorticotropin analogue, is a potent human melanocortin 1 (MC1) receptor agonist with a Ki of 0.21 nM.
    ACTH (1-17)
  • HY-P1547
    Somatostatin-25 76461-17-1 98%
    Somatostatin-25 is a endogenous neuropeptide hormone that shows inhibitory activity against secretion of growth hormone.
    Somatostatin-25
  • HY-P1557
    Somatostatin-28 (1-12) 81286-16-0 98%
    Somatostatin-28 (1-12) is a somatostatin fragment that is monitored in brain tissue to track processing of somatostatin.
    Somatostatin-28 (1-12)
  • HY-P1561
    PKG Substrate 81187-14-6 98.05%
    PKG Substrate is a selective substrate for cGMP-dependent protein kinase (PKG).
    PKG Substrate
  • HY-P1567
    β-Amyloid (10-35), amide 181427-66-7 98%
    β-Amyloid (10-35), amide is composed of 26 aa (10-35 residues of the Aβ peptide) and is the primary component of the amyloid plaques of Alzheimer’s disease.
    β-Amyloid (10-35), amide
  • HY-P1588
    Scyliorhinin II 112748-19-3 98%
    Scyliorhinin II is a selective neurokinin-3 receptor agonist, with a Ki of 2.5 nM for neurokinin-3 receptor in rat cerebral cortex.
    Scyliorhinin II
  • HY-P1594
    Dynorphin A (1-10) 79994-24-4 98%
    Dynorphin A (1-10) an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) also blocks NMDA-activated current with an IC50 of 42.0 μM.
    Dynorphin A (1-10)
  • HY-P1599
    Valorphin 144313-54-2 98%
    Valorphin is an endogenous hemoglobin β-chain (33-39) fragment with opioid analgesic activity, binds to rat mu-opioid receptor, with an IC50 of 14 nM; Valorphin also shows anti-tumor activity.
    Valorphin
  • HY-P1618
    LY-281217 105027-75-6 98%
    LY-281217 is a potent mu-opioid agonist with analgesic effects.
    LY-281217
  • HY-P1626
    Acetyl tetrapeptide-15 928007-64-1 99.49%
    Acetyl tetrapeptide-15 is a synthetic peptide. Acetyl tetrapeptide-15 is derived from endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), a human μ-opioid agonist with selective anti-nociceptive effect. Acetyl tetrapeptide-15 reduces skin hyperreactivity producing inflammatory, chronic and neuropathic pain, by increasing the threshold of neuronal excitability in μ-opioid receptor via an endorphin-like pathway. Acetyl tetrapeptide-15 is used in the cosmetics for sensitive skin.
    Acetyl tetrapeptide-15
  • HY-P1681
    GpTx-1 1661050-12-9 98%
    GpTx-1 is a peptide-based NaV1.7 sodium channel antagonist isolated from the venom of the Chilean spider Grammostola porter. GpTx-1 demonstrates potent inhibitory activity against the NaV1.7 channel with an IC50 value of 10 nM, while exhibiting excellent selectivity for NaV1.4 (IC50 = 0.301 μM) and NaV1.5 (IC50 = 4.20 μM), showing >20-fold and >950-fold selectivity respectively.
    GpTx-1
  • HY-P1691
    Leucopyrokinin 104052-00-8 98%
    Leucopyrokinin is a myotropic neuropeptide, which accelerates pupariation via central innervation, promotes tanning age dependently. Leucopyrokinin shapes the puparium by contracting and shrinking the integument.
    Leucopyrokinin
  • HY-P1716
    Neuropeptide DF2 149471-11-4 98%
    Neuropeptide DF2 is a DRNFLRFamide neuropeptide orignally isolated from crayfish. which enhances transmitter release and stimulates the amplitude of excitatory post-synaptic potentials (EPSP) through the calcium/calmodulin-dependent protein kinase.
    Neuropeptide DF2
  • HY-P1725
    Leucomyosuppressin 106884-19-9 98%
    Leucomyosuppressin, an insect neuropeptide, is an inhibitory myotropic peptide. Leucomyosuppressin inhibits evoked transmitter release at the mealworm neuromuscular junction.
    Leucomyosuppressin
  • HY-P1729
    M-2420 310427-95-3 98%
    M-2420 is a fluorogenic substrate containing β-secretase site of the Swedish mutation of amyloid precursor protein (APP).
    M-2420
  • HY-P1734
    Ac-MBP (1-11) 125366-42-9 98%
    Ac-MBP 1-11, a short peptide sequence, is the major encephalitogenic epitope in myelin basic protein (MBP).
    Ac-MBP (1-11)
  • HY-P1754
    Tetanus toxin (830-843) 119260-99-0 98%
    Tetanus toxin (830-843) is a powerful neurotoxin that reaches by retroaxonal transport and transcytosis the cytoplasm ofspinal inhibitory intemeurons and blocks their ability to release neurotransmitters.
    Tetanus toxin (830-843)
  • HY-P1760
    Allatostatin IV 123338-13-6 98%
    Allatostatin IV is an octapeptide. Allatostatins are pleiotropic neuropeptides for inhibition of juvenile hormone synthesis in insects.
    Allatostatin IV
  • HY-P1761
    Prepro VIP (111-122), human 123025-94-5 98%
    Prepro VIP (111-122), human is a prepro-vasoactive intestinal polypeptide (VIP)-derived peptide, corresponding to residues 111-122. VIP is present in the peripheral and the central nervous systems where it functions as a nonadrenergic, noncholinergic neurotransmitter or neuromodulator.
    Prepro VIP (111-122), human
  • HY-P1772
    β-Amyloid (1-17) 186319-72-2 98%
    β-Amyloid (1-17) is a peptide of β-Amyloid, stabilizes the fibres and plays a role in Aβ fibre formation.
    β-Amyloid (1-17)
Cat. No. Product Name / Synonyms Application Reactivity